Withdrawal-associated injury site pain (WISP): a descriptive case series of an opioid cessation phenomenon
- PMID: 27598412
- PMCID: PMC5113230
- DOI: 10.1097/j.pain.0000000000000710
Withdrawal-associated injury site pain (WISP): a descriptive case series of an opioid cessation phenomenon
Abstract
Withdrawal pain can be a barrier to opioid cessation. Yet, little is known about old injury site pain in this context. We conducted an exploratory mixed-methods descriptive case series using a web-based survey and in-person interviews with adults recruited from pain and addiction treatment and research settings. We included individuals who self-reported a past significant injury that was healed and pain-free before the initiation of opioids, which then became temporarily painful upon opioid cessation-a phenomenon we have named withdrawal-associated injury site pain (WISP). Screening identified WISP in 47 people, of whom 34 (72%) completed the descriptive survey, including 21 who completed qualitative interviews. Recalled pain severity scores for WISP were typically high (median: 8/10; interquartile range [IQR]: 2), emotionally and physically aversive, and took approximately 2 weeks to resolve (median: 14; IQR: 24 days). Withdrawal-associated injury site pain intensity was typically slightly less than participants' original injury pain (median: 10/10; IQR: 3), and more painful than other generalized withdrawal symptoms which also lasted approximately 2 weeks (median: 13; IQR: 25 days). Fifteen surveyed participants (44%) reported returning to opioid use because of WISP in the past. Participants developed theories about the etiology of WISP, including that the pain is the brain's way of communicating a desire for opioids. This research represents the first known documentation that previously healed, and pain-free injury sites can temporarily become painful again during opioid withdrawal, an experience which may be a barrier to opioid cessation, and a contributor to opioid reinitiation.
Conflict of interest statement
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Similar articles
-
Withdrawal-associated injury site pain prevalence and correlates among opioid-using people who inject drugs in Vancouver, Canada.Drug Alcohol Depend. 2020 Nov 1;216:108242. doi: 10.1016/j.drugalcdep.2020.108242. Epub 2020 Aug 18. Drug Alcohol Depend. 2020. PMID: 32861135 Free PMC article.
-
Linking opioid-induced hyperalgesia and withdrawal-associated injury site pain: a case report.Pain Rep. 2018 Apr 5;3(3):e648. doi: 10.1097/PR9.0000000000000648. eCollection 2018 May. Pain Rep. 2018. PMID: 29922741 Free PMC article.
-
Opioid tapering in hematopoietic progenitor cell transplant recipients.Oncol Nurs Forum. 2000 Oct;27(9):1371-80. Oncol Nurs Forum. 2000. PMID: 11058969
-
Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature.J Opioid Manag. 2010 Jul-Aug;6(4):300-3. doi: 10.5055/jom.2010.0028. J Opioid Manag. 2010. PMID: 20862910 Review.
-
Intentional intrathecal opioid detoxification in 3 patients: characterization of the intrathecal opioid withdrawal syndrome.Pain Pract. 2013 Apr;13(4):297-309. doi: 10.1111/j.1533-2500.2012.00584.x. Epub 2012 Aug 28. Pain Pract. 2013. PMID: 22925591 Review.
Cited by
-
Low-dose Initiation of Buprenorphine/naloxone for the Management of Chronic Non-cancer Pain in Patients on Long-term Opioid Therapy: A Case Series.Can J Pain. 2024 Jan 26;8(1):2310811. doi: 10.1080/24740527.2024.2310811. eCollection 2024. Can J Pain. 2024. PMID: 38571889 Free PMC article.
-
Transcranial Direct Current Stimulation to Improve the Dysfunction of Descending Pain Modulatory System Related to Opioids in Chronic Non-cancer Pain: An Integrative Review of Neurobiology and Meta-Analysis.Front Neurosci. 2019 Nov 18;13:1218. doi: 10.3389/fnins.2019.01218. eCollection 2019. Front Neurosci. 2019. PMID: 31803005 Free PMC article.
-
Opioid-Induced Tolerance and Hyperalgesia.CNS Drugs. 2019 Oct;33(10):943-955. doi: 10.1007/s40263-019-00660-0. CNS Drugs. 2019. PMID: 31578704 Review.
-
Oxycodone self-administration and withdrawal behaviors in male and female Wistar rats.Psychopharmacology (Berl). 2020 May;237(5):1545-1555. doi: 10.1007/s00213-020-05479-y. Epub 2020 Feb 29. Psychopharmacology (Berl). 2020. PMID: 32114633 Free PMC article.
-
Canadian Guidelines on Opioid Use Disorder Among Older Adults.Can Geriatr J. 2020 Mar 30;23(1):123-134. doi: 10.5770/cgj.23.420. eCollection 2020 Mar. Can Geriatr J. 2020. PMID: 32226571 Free PMC article.
References
-
- Akbari E. The role of cyclo-oxygenase inhibitors in attenuating opioid-induced tolerance, hyperalgesia, and dependence. Med Hypotheses 2012;78:102–6. - PubMed
-
- Albutt C. On the abuse of hypodermic injections of morphia. Practitioner 1870;3:327–30.
-
- Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006;104:570–87. - PubMed
-
- Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. PAIN 2003;106:49–57. - PubMed
-
- Arout CA, Caldwell M, McCloskey DP, Kest B. C-Fos activation in the periaqueductal gray following acute morphine-3beta-D-glucuronide or morphine administration. Physiol Behav 2014;130:28–33. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous